Drug intelligence / Profile preview

human interleukin-2 + TCB2c

Development stage: Preclinical
Lead developer: Selecxine
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Intravenous, Subcutaneous

Overview

human interleukin-2 + TCB2c is an experimental **cytokine-antibody complex immunotherapy** composed of recombinant human interleukin-2 bound to TCB2c, a humanized anti-IL-2 monoclonal antibody derived from TCB2. TCB2c acts as an IL-2R\u03b1 mimetic that blocks IL-2 engagement with IL-2 receptor alpha CD25, thereby biasing IL-2 signaling away from CD25-high regulatory T cells and toward IL-2 receptor beta and common gamma chain expressing CD8-positive T cells and natural killer cells. In preclinical tumor models, this IL-2/antibody complex showed enhanced antitumor activity and synergized with checkpoint blockade such as anti-CTLA-4 or anti-PD-1 therapy. The program appears to be a preclinical oncology biologic intended to improve the therapeutic index of IL-2 by selectively expanding cytotoxic lymphocytes while minimizing Treg activation.

Other names: human interleukin-2 + TCB2chIL-2/TCB2chuman IL-2 + TCB2chuman interleukin-2/TCB2c complexIL-2/TCB2c complex

Targets

IL2RB (IL-2 receptor beta chain)IL-2Rα (Interleukin-2 receptor subunit alpha)IL-2 (Interleukin 2)

Beyond the preview

Go deeper on human interleukin-2 + TCB2c.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on human interleukin-2 + TCB2c.

Explore the full profile